A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation.

@article{Jakubowski2014AP1,
  title={A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation.},
  author={Joseph A. Jakubowski and Chunmei Zhou and Stipo Jurcevic and Kenneth J. Winters and D. Richard Lachno and Andrew L Frelinger and Neehar Gupta and Jo Howard and Christopher D. Payne and Timothy G K Mant},
  journal={Thrombosis research},
  year={2014},
  volume={133 2},
  pages={190-5}
}
INTRODUCTION Prasugrel, a P2Y₁₂ adenosine diphosphate (ADP) receptor antagonist effectively inhibits ADP-mediated platelet activation and aggregation, and may be useful in reducing vaso-occlusive crises in sickle cell disease (SCD). In this study, we assess the effect of prasugrel on biomarkers of platelet activation and coagulation in patients with SCD. MATERIALS AND METHODS Twelve adult patients with SCD and 13 healthy subjects were examined before and after 12 ± 2 days of 5.0 or 7.5 mg/day… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Emerging drugs for sickle cell anemia.

Expert opinion on emerging drugs • 2015
View 1 Excerpt

Similar Papers

Loading similar papers…